Professor Iain Hagan

Cell Division Group Leader

Iain is a Senior Group Leader at the Institute, running the Cell Division lab. He is passionate about the study of cell division and cell cycle control. Using sophisticated manipulation of yeast as a model system, he has defined fundamental principles of cell cycle control and division that have informed our understanding of cancer cell proliferation to refine therapeutic approaches.

About Professor Iain Hagan

After completing his PhD studies Iain Hagan went to Japan on a 4-year postdoctoral fellowship with Professor Mitsuhiro Yanagida in Kyoto University. He returned to the UK in 1993 with a Cancer Research Campaign Return Fellowship to establish a group in The University of Manchester. He continued to work in what later became the Faculty of Life Sciences at The University of Manchester, with further Cancer Research Campaign Fellowship support before moving to the Cancer Research UK Manchester Institute in 2001.

In 1999, Iain was awarded the Human Frontier Science Program 10th Anniversary Medal and in 2001 was the recipient of the BSCB Hooke Medal. Iain is currently a Senior Group Leader at the CRUK Manchester Institute. In 2009, he was elected to full membership of the European Molecular Biology Organisation (EMBO). In 2016, Iain was awarded a Wellcome Trust Investigator Award to study spatial and temporal control of mitotic commitment.

Iain is Chair of the internal Grants Committee that reviews all our grant applications. From 2021 until 2023, he was Deputy Director at the CRUK Manchester Institute.

Groups

Qualifications

  • PhD in Cell Biology | 1987 | University College London & ICRF
  • BSc in Biochemistry | 1984 | University College London

Interests

  • Control and execution of mitosis
  • Control of protein phosphatases
  • Mitotic spindle

Why I work at CRUK MI

“The Institute is made of some fantastic people who are dedicated to their research and want to make a difference to the lives of cancer patients. It is a real pleasure and honour to work alongside these great scientists and to nurture our early career researchers.”

Visit Research Group

The inappropriate proliferation of cancer cells can arise from unchecked cell division, a failure to engage cell death pathways, or simultaneous changes in both. Understanding how the diverse cues are integrated to co-ordinate cell division and death is therefore key to understanding the biology of cancer. The Cell Division group study cell cycle controls that determine when a cell commits to the physical process of genome segregation, mitosis.

Because the regulatory networks that control cell division are highly conserved, we use both unicellular fission yeast and human cells in our investigations as the yeast work identifies core principles with which to frame questions to ask of the more complex context of human cell division. Our yeast work addresses how signals from the broad range of pathways are integrated by regulatory relays on neighbouring scaffolds on the centrosome to generate a single signal to trigger division when the time is right.

Complementary studies are asking whether similar controls operate in human cells and characterises one of the key cell cycle checkpoint molecules that determines when mitosis begins, PKMYT1.

Get in touch

Please enable JavaScript in your browser to complete this form.
Filter by group
Filter by group leader
Filter by research topic
Filter by year
Search publications

https://doi.org/10.1186/s12943-024-02157-x

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

12 November 2024

Institute Authors (1)

Amaya Viros

Labs & Facilities

Genome Editing and Mouse Models

array(1) { [0]=> int(2947) }

Research Group

Skin Cancer & Ageing

array(1) { [0]=> int(2344) }

https://doi.org/10.1186/s13045-024-01610-0

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

8 October 2024

Institute Authors (6)

Georges Lacaud, Mathew Sheridan, Michael Lie-a-ling, Liam Clayfield, Jessica Whittle, Jingru Xu

Research Group

Stem Cell Biology

int(2449)

/wp-content/uploads/2024/11/Annual-Report-2023.pdf

2023 Annual Report

13 September 2024

https://doi.org/10.1126/science.adh7954

Vitamin D regulates microbiome-dependent cancer immunity

25 April 2024

Institute Authors (1)

Evangelos Giampazolias

Research Group

Cancer Immunosurveillance

array(1) { [0]=> int(2341) }

https://doi.org/10.1038/s41684-024-01363-w

Streamlining mouse genome editing by integrating AAV repair template delivery and CRISPR-Cas electroporation

10 April 2024

Institute Authors (1)

Natalia Moncaut

Labs & Facilities

Genome Editing and Mouse Models

array(1) { [0]=> int(2947) }

https://www.biorxiv.org/content/10.1101/2023.12.13.568969v1

A novel human model to deconvolve cell-intrinsic phenotypes of genetically dysregulated pathways in lung squamous cell carcinoma

14 December 2023

Institute Authors (3)

Carlos Lopez-Garcia, Caroline Dive, Anthony Oojageer

Research Group

Translational Lung Cancer Biology

array(1) { [0]=> int(2321) }

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Institute life in Manchester

We strive to make our community a welcoming, caring and enthusiastic one, fuelling ambition with opportunities for training and mentoring to help us all achieve our personal and professional goals.

“We are so pleased to have received the funding to enable us to test our hypothesis in the lab. If we can create a new medicine that can precisely target a specific type of cell within the tumour, and restore anti-cancer immune responses, this will be a game-changer for oesophageal cancer patients “

Sara Valpione

Former Institute Clinical Fellow and now Clinician in Residence within the CRUK National Biomarker Centre

“My charity bake sales – known as “David’s Great British Bake Off” – are always a hit, home baked products taste so much better than shop bought and are greatly appreciated by staff!”

David Jenkins

Purchasing Officer

“We’ve seen some remarkable responses, with an improvement for some patients within days. This is an early phase trial so there’s a lot more work to do. But the data we have so far is very encouraging and could help many thousands of people in the future”

Tim Somervaille

Senior Group Leader

“It is a pleasure to introduce my team who work to deliver our research goals. We work in a friendly and collaborative environment, supporting each other’s projects.  “

Amaya Virós

CRUK Advanced Clinician Scientist Fellow